These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
404 related articles for article (PubMed ID: 33648385)
21. Novel Therapies in Acute Migraine Management: Small-Molecule Calcitonin Gene-Receptor Antagonists and Serotonin 1F Receptor Agonist. Joyner KR; Morgan KW Ann Pharmacother; 2021 Jun; 55(6):745-759. PubMed ID: 32993366 [TBL] [Abstract][Full Text] [Related]
22. Situational prevention in migraine: are we doing the right thing? Pellesi L; Martelletti P J Headache Pain; 2024 Aug; 25(1):137. PubMed ID: 39174943 [TBL] [Abstract][Full Text] [Related]
23. Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial. Yu S; Guo A; Wang Z; Liu J; Tan G; Yang Q; Zhang M; Yibulaiyin H; Chen H; Zhang Y; Croop R; Sun Y; Liu Y; Zhao Q; Lu Z J Headache Pain; 2024 Apr; 25(1):57. PubMed ID: 38627638 [TBL] [Abstract][Full Text] [Related]
24. Update of Gepants in the Treatment of Chronic Migraine. Cho S; Kim BK Curr Pain Headache Rep; 2023 Oct; 27(10):561-569. PubMed ID: 37656319 [TBL] [Abstract][Full Text] [Related]
27. Gepants - a long way to cure: a narrative review. Altamura C; Brunelli N; Marcosano M; Fofi L; Vernieri F Neurol Sci; 2022 Sep; 43(9):5697-5708. PubMed ID: 35650458 [TBL] [Abstract][Full Text] [Related]
28. CGRP and migraine: from bench to bedside. Edvinsson L Rev Neurol (Paris); 2021 Sep; 177(7):785-790. PubMed ID: 34275653 [TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial. Yu S; Kim BK; Guo A; Kim MH; Zhang M; Wang Z; Liu J; Moon HS; Tan G; Yang Q; McGrath D; Hanna M; Stock DA; Gao Y; Croop R; Lu Z Lancet Neurol; 2023 Jun; 22(6):476-484. PubMed ID: 37210098 [TBL] [Abstract][Full Text] [Related]
30. First real-world study on the effectiveness and tolerability of rimegepant for acute migraine therapy in Chinese patients. Yang Z; Wang X; Niu M; Wei Q; Zhong H; Li X; Yuan W; Xu W; Zhu S; Yu S; Liu J; Yan J; Kang W; Huang P J Headache Pain; 2024 Sep; 25(1):160. PubMed ID: 39333875 [TBL] [Abstract][Full Text] [Related]
31. Pharmacology of erenumab in human isolated coronary and meningeal arteries: Additional effect of gepants on top of a maximum effect of erenumab. de Vries T; Rubio-Beltrán E; van den Bogaerdt A; Dammers R; Danser AHJ; Snellman J; Bussiere J; MaassenVanDenBrink A Br J Pharmacol; 2024 Jun; 181(12):1720-1733. PubMed ID: 38320397 [TBL] [Abstract][Full Text] [Related]
32. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018. Tepper SJ Headache; 2018 Nov; 58 Suppl 3():276-290. PubMed ID: 30403405 [TBL] [Abstract][Full Text] [Related]
33. Real world considerations for newly approved CGRP receptor antagonists in migraine care. Scuteri D; Tonin P; Nicotera P; Bagetta G; Corasaniti MT Expert Rev Neurother; 2022 Mar; 22(3):221-230. PubMed ID: 35240905 [TBL] [Abstract][Full Text] [Related]
34. Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy. Holland PR; Goadsby PJ Neurotherapeutics; 2018 Apr; 15(2):304-312. PubMed ID: 29556965 [TBL] [Abstract][Full Text] [Related]
35. Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives. De Matteis E; Guglielmetti M; Ornello R; Spuntarelli V; Martelletti P; Sacco S Expert Rev Neurother; 2020 Jun; 20(6):627-641. PubMed ID: 32434430 [TBL] [Abstract][Full Text] [Related]
36. Raynaud's phenomenon associated with calcitonin gene-related peptide receptor antagonists case report. Bedrin K; Ailani J; Dougherty C Headache; 2022 Nov; 62(10):1419-1423. PubMed ID: 36426766 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of Rimegepant 75 mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial. Lipton RB; Thiry A; Morris BA; Croop R J Pain Res; 2024; 17():2431-2441. PubMed ID: 39070853 [TBL] [Abstract][Full Text] [Related]
38. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review. Yuan H; Spare NM; Silberstein SD Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020 [TBL] [Abstract][Full Text] [Related]
39. Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine. Popoff E; Johnston K; Croop R; Thiry A; Harris L; Powell L; Coric V; L'Italien G; Moren J Headache; 2021 Jun; 61(6):906-915. PubMed ID: 34021585 [TBL] [Abstract][Full Text] [Related]
40. Anti-migraine Calcitonin Gene-Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice. Mulder IA; Li M; de Vries T; Qin T; Yanagisawa T; Sugimoto K; van den Bogaerdt A; Danser AHJ; Wermer MJH; van den Maagdenberg AMJM; MaassenVanDenBrink A; Ferrari MD; Ayata C Ann Neurol; 2020 Oct; 88(4):771-784. PubMed ID: 32583883 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]